Free Trial

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Director Peter A. Thompson Sells 1,176,332 Shares

Corvus Pharmaceuticals logo with Medical background

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) Director Peter A. Thompson sold 1,176,332 shares of Corvus Pharmaceuticals stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $4.16, for a total value of $4,893,541.12. Following the completion of the sale, the director owned 7,165,006 shares in the company, valued at approximately $29,806,424.96. This trade represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Corvus Pharmaceuticals Stock Down 1.1%

Shares of CRVS traded down $0.05 during trading on Friday, reaching $3.94. The company's stock had a trading volume of 313,955 shares, compared to its average volume of 827,273. The company has a market cap of $268.25 million, a price-to-earnings ratio of -4.02 and a beta of 0.58. The company has a fifty day moving average of $3.83 and a two-hundred day moving average of $4.24. Corvus Pharmaceuticals, Inc. has a twelve month low of $1.75 and a twelve month high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). As a group, equities analysts forecast that Corvus Pharmaceuticals, Inc. will post -0.63 EPS for the current fiscal year.

Institutional Investors Weigh In On Corvus Pharmaceuticals

A number of institutional investors have recently modified their holdings of CRVS. Sowell Financial Services LLC acquired a new stake in shares of Corvus Pharmaceuticals in the first quarter valued at approximately $38,000. Virtus ETF Advisers LLC bought a new position in Corvus Pharmaceuticals in the 4th quarter worth approximately $47,000. PKS Advisory Services LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at approximately $56,000. Alpine Global Management LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at approximately $62,000. Finally, ExodusPoint Capital Management LP bought a new stake in Corvus Pharmaceuticals during the 4th quarter valued at $72,000. Institutional investors own 46.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CRVS. Wall Street Zen downgraded shares of Corvus Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, May 20th. Oppenheimer reissued an "outperform" rating and issued a $17.00 price objective (up previously from $15.00) on shares of Corvus Pharmaceuticals in a research report on Friday, May 9th. Mizuho set a $11.00 price target on shares of Corvus Pharmaceuticals and gave the stock an "outperform" rating in a research report on Tuesday, May 20th. Finally, HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $15.00.

Check Out Our Latest Stock Report on CRVS

Corvus Pharmaceuticals Company Profile

(Get Free Report)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.

Recommended Stories

Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?

Before you consider Corvus Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.

While Corvus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines